• A Pogossian, C de Moreuil, C Lemarié, B Rouvière, M Delplanque, B Molina, L Prophette, and E Le Moigne.
• UMR 1304, GETBO, université de Bretagne Occidentale, Brest, France; Département de médecine interne, médecine vasculaire et pneumologie, CHU Brest, Brest, France. Electronic address: alexanpogossian@gmail.com.
• Rev Med Interne. 2022 Dec 1; 43 (12): 703712703-712.

AbstractInnate immunity, and more specifically the complement system, has arised renewed interest in the medical field in recent years. Many innovative complement-inhibiting drugs have appeared, acting at various levels of the complement cascade. These drugs have made it possible to transform poor prognosis of certain diseases. Many of them are currently being tested in clinical trials for various indications. Many questions appear about their optimal use and their future indications. This article recalls the fundamental role of the complement system in the human organism. It then discusses the diseases in which the complement is involved on the pathophysiological level. The third part details the different classes of complement inhibitors and briefly recalls the indications for which these treatments seem the most promising. Finally, we end with a discussion that highlights the different aspects and questions induced by these new treatments.Copyright © 2022 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

8 keywords...

hide…